Physiomics PLC Conference attendance and presentation

Data : 30/04/2019 @ 10:00
Fonte : RNS Non-Regulatory
Ativo : Physiomics Plc (PYC)
Cotação : 2.9  0.15 (5.45%) @ 11:44
Cotação Gráfico

Physiomics PLC Conference attendance and presentation

TIDMPYC

Physiomics PLC

30 April 2019

30(th) April 2019

Physiomics plc

("Physiomics") or ("the Company")

Conference attendance and presentation

Physiomics presents at the BioTrinity 2019 meeting in London

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it presented today at the BioTrinity 2019 annual conference in London. The presentation is available on the "resources" section of our website here https://www.physiomics.co.uk/wp-content/uploads/2019/04/Physiomics-Presentation-Biotrinity-2019.pdf.

The Company also took the opportunity to meet with a number of existing and potential new clients as well as to keep up to date with the latest in oncology drug development.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

WH Ireland Limited (NOMAD)

Katy Mitchell

James Sinclair-Ford

+44 (0) 161 832 2174

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Notes to Editor

This is an RNS Reach

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour(TM) has been confirmed by over 70 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRACKKDPBBKDPQN

(END) Dow Jones Newswires

April 30, 2019 09:00 ET (13:00 GMT)

Physiomics (LSE:PYC)
Gráfico Histórico do Ativo

1 Ano : De Out 2018 até Out 2019

Click aqui para mais gráficos Physiomics.

Physiomics (LSE:PYC)
Gráfico Intraday do Ativo

Hoje : Quarta, 23 de Outubro de 2019

Click aqui para mais gráficos Physiomics.
Seu Histórico Recente
BOV
VALE5
Vale PNA
BOV
IBOV
iBovespa
BOV
PETR4
Petrobras
BOV
IGBR3
IGB SA
FX
USDBRL
Dólar EUA ..
Ações já vistas aparecerão nesta caixa, facilitando a volta para cotações pesquisadas anteriormente.

Registre-se agora para criar sua própria lista de ações customizada.

Cotações da NYSE e AMEX têm defasagem de no mínimo 20 minutos.
Quaisquer outras cotações têm defasagem de no mínimo 15 minutos quando não especificado.
Em caso de dúvidas por favor entre em contato com o suporte: suporte@advfn.com.br ou (11) 4950 5808.
P: V:br D:20191023 19:31:49